Podcasts
>
Research
>

Final Results From Early Trials on a Vaccine to Prevent TNBC

Inflammation and immunity researcher Justin Johnson outlines the latest findings on the vaccine and outlines next steps for the research.

Published on December 11, 2025

https://images.ctfassets.net/zzorm7zihro2/5WJTLco64Acf1DDTIpoAC1/aad4da300af4be2029d623a7834d0361/JohnsonBCVaccine_2466x1644.jpg
00:00
00:00

At the 2025 San Antonio Breast Cancer Symposium, Justin Johnson, PhD, presented a poster detailing the final results from three groups of people in a phase I trial on a vaccine to prevent triple-negative breast cancer.

Listen to the episode to hear Dr. Johnson explain:

  • why the vaccine targets the alpha-lactalbumin protein

  • the safety and dose results of the study

  • what’s next for the research

Scroll down to below the “About the guest” information to read a transcript of this podcast.


About the guests
 
Justin Johnson, PhD headshot
Justin Johnson, PhD

Justin Johnson, PhD, is a program manager in the Department of Inflammation and Immunity at the Cleveland Clinic.

 

This podcast episode is made possible by Lilly.

 
Listen to more episodes on 'Research'
See all episodes
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate